Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
CGM setup and interpretation codes identify who prescribes diabetes technology. Main billing specialties: endocrinology, internal medicine and family practice.
Medicare fee-for-service CGM & insulin pump management cases in the 51 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (248 state-years, 2020–2024): a close guide.
Professional codes (what the surgeon bills): CPT 95249, 95250, 95251.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 588 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 14 companies. The most active:
The 10 busiest do 11% of the cases CMS names in California; 229 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
Every procedure · Markets by state · Device companies · Compare two states
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 513 | 68,597+18%/yr | +18%/yr | 20.10.8× | 91% | 127,400 in 2030+11%/yr |
| Florida | 404 | 65,371+15%/yr | +15%/yr | 28.71.1× | 96% | 130,100 in 2030+12%/yr |
| Texas | 452 | 65,364+17%/yr | +17%/yr | 29.81.1× | 92% | 129,200 in 2030+12%/yr |
| New York | 496 | 58,834+16%/yr | +16%/yr | 31.71.2× | 89% | 98,600 in 2030+9%/yr |
| Illinois | 293 | 40,924+22%/yr | +22%/yr | 29.21.1× | 76% | 73,100 in 2030+10%/yr |
| New Jersey | 303 | 39,418+16%/yr | +16%/yr | 37.11.4× | 99% | 69,600 in 2030+10%/yr |
| Pennsylvania | 334 | 37,842+26%/yr | +26%/yr | 27.21.0× | 80% | 63,900 in 2030+9.1%/yr |
| Ohio | 278 | 30,536+34%/yr | +34%/yr | 27.11.0× | 66% | 55,500 in 2030+10%/yr |
| North Carolina | 229 | 28,955+18%/yr | +18%/yr | 28.61.1× | 87% | 48,600 in 2030+9%/yr |
| Georgia | 210 | 27,583+22%/yr | +22%/yr | 31.31.2× | 99% | 50,800 in 2030+11%/yr |
| Maryland | 171 | 26,549+30%/yr | +30%/yr | 29.81.1× | 87% | 49,300 in 2030+11%/yr |
| Massachusetts | 240 | 25,322+25%/yr | +25%/yr | 26.41.0× | 64% | 50,400 in 2030+12%/yr |
| Virginia | 186 | 25,175+32%/yr | +32%/yr | 23.70.9× | 75% | 49,200 in 2030+12%/yr |
| Indiana | 163 | 22,848+22%/yr | +22%/yr | 31.91.2× | 89% | 37,600 in 2030+8.6%/yr |
| Michigan | 215 | 22,586+13%/yr | +13%/yr | 26.21.0× | 68% | 36,200 in 2030+8.2%/yr |
| Missouri | 161 | 21,566+29%/yr | +29%/yr | 34.11.3× | 80% | 38,800 in 2030+10%/yr |
| Tennessee | 150 | 20,740+27%/yr | +27%/yr | 29.01.1× | 93% | 38,400 in 2030+11%/yr |
| Arizona | 119 | 19,293+31%/yr | +31%/yr | 25.61.0× | 94% | 36,700 in 2030+11%/yr |
| South Carolina | 108 | 17,936+27%/yr | +27%/yr | 25.81.0× | 93% | 35,200 in 2030+12%/yr |
| Washington | 142 | 16,753+14%/yr | +14%/yr | 21.50.8× | 78% | 28,600 in 2030+9.3%/yr |
| Kansas | 76 | 13,034+33%/yr | +33%/yr | 31.91.2× | 84% | 23,200 in 2030+10%/yr |
| Wisconsin | 144 | 12,963+33%/yr | +33%/yr | 22.50.8× | 71% | 25,100 in 2030+12%/yr |
| Kentucky | 110 | 12,522+26%/yr | +26%/yr | 26.81.0× | 83% | 22,100 in 2030+9.9%/yr |
| Minnesota | 116 | 12,114+19%/yr | +19%/yr | 26.21.0× | 80% | 25,600 in 2030+13%/yr |
| Oklahoma | 89 | 11,902+33%/yr | +33%/yr | 24.20.9× | 84% | 19,400 in 2030+8.5%/yr |
| Alabama | 73 | 11,837+23%/yr | +23%/yr | 26.41.0× | 81% | 19,400 in 2030+8.6%/yr |
| Mississippi | 54 | 11,559+40%/yr | +40%/yr | 30.41.1× | 85% | 20,500 in 2030+10%/yr |
| Louisiana | 83 | 11,500+25%/yr | +25%/yr | 27.61.0× | 78% | 18,600 in 2030+8.3%/yr |
| Colorado | 85 | 11,013+29%/yr | +29%/yr | 22.20.8× | 86% | 21,300 in 2030+12%/yr |
| Connecticut | 137 | 10,569+19%/yr | +19%/yr | 31.31.2× | 79% | 18,600 in 2030+9.9%/yr |
| Arkansas | 47 | 10,160+31%/yr | +31%/yr | 26.51.0× | 84% | 16,600 in 2030+8.6%/yr |
| Iowa | 54 | 9,706+30%/yr | +30%/yr | 21.60.8× | 65% | 17,100 in 2030+9.9%/yr |
| Nebraska | 54 | 8,132+36%/yr | +36%/yr | 30.91.2× | 76% | 14,300 in 2030+9.9%/yr |
| New Hampshire | 60 | 7,226+35%/yr | +35%/yr | 31.51.2× | 56% | 14,600 in 2030+12%/yr |
| Oregon | 67 | 6,744+25%/yr | +25%/yr | 15.80.6× | 74% | 15,000 in 2030+14%/yr |
| Utah | 44 | 6,339+36%/yr | +36%/yr | 28.41.1× | 86% | 10,700 in 2030+9.2%/yr |
| Nevada | 41 | 5,936+7.7%/yr | +7.7%/yr | 20.30.8× | 95% | 10,900 in 2030+11%/yr |
| Delaware | 25 | 4,890+35%/yr | +35%/yr | 28.21.1× | 80% | 8,660 in 2030+10%/yr |
| Montana | 28 | 4,887+30%/yr | +30%/yr | 25.41.0× | 42% | 8,940 in 2030+11%/yr |
| West Virginia | 43 | 4,488+28%/yr | +28%/yr | 21.10.8× | 34% | 8,070 in 2030+10%/yr |
| South Dakota | 26 | 3,993+45%/yr | +45%/yr | 30.41.1× | 9% | 7,150 in 2030+10%/yr |
| Idaho | 36 | 3,935+37%/yr | +37%/yr | 19.00.7× | 46% | 8,300 in 2030+13%/yr |
| New Mexico | 26 | 3,176+18%/yr | +18%/yr | 13.60.5× | 77% | 6,050 in 2030+11%/yr |
| Maine | 30 | 2,429+36%/yr | +36%/yr | 15.10.6× | 18% | 4,270 in 2030+9.9%/yr |
| North Dakota | 12 | 1,926+24%/yr | +24%/yr | 19.10.7× | 48% | 3,400 in 2030+9.9%/yr |
| Rhode Island | 19 | 1,789+12%/yr | +12%/yr | 19.20.7× | 87% | 3,570 in 2030+12%/yr |
| Vermont | 14 | 1,742+68%/yr | +68%/yr | 15.10.6× | 23% | 4,210 in 2030+16%/yr |
| Alaska | 15 | 1,644+38%/yr | +38%/yr | 13.60.5× | 64% | 4,150 in 2030+17%/yr |
| District of Columbia | 17 | 1,276+12%/yr | +12%/yr | 20.10.8× | 100% | 2,370 in 2030+11%/yr |
| Hawaii | 13 | 1,091+42%/yr | +42%/yr | 8.40.3× | 81% | 2,360 in 2030+14%/yr |
| Wyoming | 3 | 378+3.6%/yr | +3.6%/yr | 3.50.1× | 100% | 410 in 2030+1.5%/yr |
Product codes: LZG (pump, infusion, insulin), MDS (sensor, glucose, invasive), OYC (pump, infusion, insulin, to be used with invasive glucose sensor), OZO (automated insulin dosing , threshold suspend), OZP (automated insulin dosing device system, single hormonal control), OZQ (automated insulin dosing device system, bihormonal control), QBJ (integrated continuous glucose monitoring system, factory calibrated), QFG (alternate controller enabled insulin infusion pump), QJS (interoperable automated glycemic controller, insulin suspend), QLG (integrated continuous glucose monitoring system, factory calibrated, not for use with automated insulin delivery systems), SFI (sensor, glucose, invasive, component of automated insulin delivery system). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved −9 pts since 2019, to 84%.
In 2025, 15 companies reported engagement with surgeons in the covered states worth $13M in consulting, speaking, meals and travel tied to these products, about $1,908 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 33 recalled product lines (8 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.